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We have identified a new human cDNA, L-amino acid
transporter-2 (LAT-2), that induces a system L trans-
port activity with 4F2hc (the heavy chain of the sur-
face antigen 4F2, also named CD98) in oocytes. Human
LAT-2 is the fourth member of the family of amino acid
transporters that are subunits of 4F2hc. The amino
acid transport activity induced by the co-expression of
4F2hc and LAT-2 was sodium-independent and showed
broad specificity for small and large zwitterionic
amino acids, as well as bulky analogs (e.g. BCH (2-
aminobicyclo-(2,2,1)-heptane-2-carboxylic acid)). This
transport activity was highly trans-stimulated, sug-
gesting an exchanger mechanism of transport. Expres-
sion of tagged N-myc-LAT-2 alone in oocytes did not
induce amino acid transport, and the protein had an
intracellular location. Co-expression of N-myc-LAT-2
and 4F2hc gave amino acid transport induction and
expression of N-myc-LAT-2 at the plasma membrane of
the oocytes. These data suggest that LAT-2 is an addi-
tional member of the family of 4F2 light chain sub-
units, which associates with 4F2hc to express a system
L transport activity with broad specificity for zwitte-
rionic amino acids. Human LAT-2 mRNA is expressed
in kidney >>> placenta >> brain, liver > spleen, skele-
tal muscle, heart, small intestine, and lung. Human
LAT-2 gene localizes at chromosome 14q11.2–13 (13 cR
or ;286 kb from marker D14S1349). The high expres-
sion of LAT-2 mRNA in epithelial cells of proximal
tubules, the basolateral location of 4F2hc in these
cells, and the amino acid transport activity of LAT-2
suggest that this transporter contributes to the renal
reabsorption of neutral amino acids in the basolateral
domain of epithelial proximal tubule cells.
Last year, three amino acid transporter cDNAs (LAT-1,
y1LAT-1, and y1LAT-2)1 were identified as subunits of the
heavy chain of the cell surface antigen 4F2 (4F2hc, also named
CD98) (1–3). These subunits co-express amino acid transport
activity with 4F2hc in oocytes (i.e. system L for LAT-1, and
system y1L for y1LAT-1 and y1LAT-2) (1–4). The role of this
family of proteins in amino acid transport has recently been
demonstrated by the fact that mutations in the y1LAT-1 gene
cause lysinuric protein intolerance, an inherited amino acid-
uria due to a defective renal reabsorption mechanism of dibasic
amino acids (5, 6). The structural and functional similarities
between 4F2hc and its homologous protein rBAT suggest that
a member of this family of subunits might be the subunit of
rBAT needed to fully express the amino acid transport system
bo,1 activity (reviewed in Refs. 7 and 8). After the identification
of rBAT as the Type I cystinuria gene (9), this subunit is a good
candidate for non-Type I cystinuria (7). A search throughout
gene data bases suggests that there may be as many as four
new human members of the family of subunits of 4F2hc and
rBAT.
Kanai and co-workers (1) identified rat LAT-1 (also known as
TA1) by co-expression cloning with 4F2hc in oocytes. The co-
expressed transport activity shows clear characteristics of the
amino acid transport system L: high affinity (Km in the low mM
range), sodium-independent, and trans-stimulated transport
for large zwitterionic amino acids. Some of these characteris-
tics have also been demonstrated for the human (E16, Ref. 2)
and Xenopus laevis orthologs of LAT-1 (ASUR4, Ref. 2; IU12,
Ref. 3). System L is almost ubiquitous (10), and variants of
system L have been described (11, 12). The expression of rat
LAT-1 is not ubiquitous, and it is not present in tissues such as
kidney and liver (1), which suggests that homologs of LAT-1
might encode system L amino acid transporter variants.
In this study we have identified the fourth human member
(LAT-2) of this family of amino acid transporters. LAT-2 does
not induce transport of amino acids in oocytes when it is in-
jected alone, but a variant of system L transport activity (i.e.
with broad specificity for small and large zwitterionic amino
acids) is co-expressed when LAT-2 is injected with 4F2hc. We
demonstrate here that co-expression of LAT-2 with 4F2hc
brings the former to the oocyte plasma membrane. Its expres-
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sion in the epithelial cells of the proximal tubule suggests a role
of LAT-2/4F2hc in the renal reabsorption of neutral amino
acids.
EXPERIMENTAL PROCEDURES
PCR Amplification, Sequencing, and LAT-2 cDNA Construction—For
PCR amplification, first-strand cDNA was synthesized from 5 mg of
total RNA purified from opossum kidney (13) cells using SuperScript II
kit (Life Technologies, Inc.). Two degenerate forward and reverse prim-
ers were designed based on two highly conserved regions among the
first known members of this family of amino acid transporters. PCR
amplification, subcloning into pGEM-T easy vector (Promega), and se-
quencing were carried out as described elsewhere (3).
The open reading frame (ORF) of LAT-2 was obtained from two
partial human LAT-2 cDNA clones (IMAGE No. 322502 and No.
267204). Clone 322502 was cut with NotI and AvrII to create the 59-end
fragment of LAT-2 (from nt 1 to 1152 of the LAT-2 cDNA). Clone 267204
was digested with EcoRI and AvrII to create the 39-end fragment of the
LAT-2 coding sequence (nt 1152 to 39-end of the LAT-2 cDNA) ligated to
the pT7T3D vector. Both fragments were ligated to create a LAT-2
cDNA fragment covering the ORF (59-end to nt 2050; see Fig. 1) in
pT7T3D vector. To improve expression in oocytes, an SspI-NotI frag-
ment of LAT-2 was cloned into pNKS2-myc NotI vector (a gift from G.
Schmalzing; Ref. 14). To create an N-myc-tagged LAT-2 cDNA,
pT7T3D-LAT-2 was PCR-amplified with primers M13 forward (16-mer)
and 59-ACGTCTAGTCGACATGGAAGAAGGAGCCAGGCAC-39 (con-
taining a SalI site and the first 21 nt of the ORF of LAT-2). The PCR
product was digested with SalI and NotI. The resulting fragment of
LAT-2 was cloned into pNKS2-myc NotI. The N-myc-tagged LAT-2
cDNA was tested by sequencing. All sequences carried out in this work
were performed in both directions with d-rhodamine dye terminator
cycle sequencing ready reaction kit (Perkin-Elmer). The sequence reac-
tions were analyzed with an Abi Prism 377 DNA sequencer.
Oocytes, Injections, and Uptake Measurements—Oocyte origin, man-
agement, and injections were as described elsewhere (15, 16). Defollicu-
lated stage VI X. laevis oocytes were injected with 10 ng/oocyte human
4F2hc, human LAT-2, N-myc-LAT-2, or X. laevis IU12 cRNA. Synthesis
of human 4F2hc cRNA (17) was as described (18). X. laevis LAT-1 (i.e.
IU12) was a gift from Y. B. Shi (19), and the cRNA was synthesized as
described elsewhere (3). Human LAT-2 cRNA was obtained by cutting
the cDNA with NotI and using T7 polymerase.
Influx rates of L-[3H]arginine, L-[3H]leucine, L-[3H]alanine, and
L-[3H]glutamine (Amersham Pharmacia Biotech) were measured in 100
mM NaCl or 100 mM CholineCl medium at the indicated number of days
after injection and under linear conditions as described (15). Amino acid
transport rates obtained with oocytes injected with water (50 nl) were
similar to those of noninjected oocytes (data not shown). For L-[3H]iso-
leucine efflux measurements, groups of five cRNA-injected or nonin-
jected oocytes were incubated with 50 mM L-[3H]isoleucine (3 mCi/ml) for
the indicated period of time (see legend to Fig. 7). Efflux was measured
as described elsewhere (20).
Computer Analysis—Amino acid or nucleotide sequence homology
search and the prediction of transmembrane segments of LAT-2 were
performed as indicated elsewhere (3).
Northern Blot Analysis—A human adult poly(A1) membrane from
CLONTECH (Palo Alto, CA) was used. The insert of clone 267204 was
separated from the pT7T3D vector by NotI-EcoRI digestion. This ;1-kb
DNA fragment was purified, labeled with [a-32P]dCTP (Amersham
Pharmacia Biotech) using a random oligonucleotide-priming labeling
kit (Amersham Pharmacia Biotech), and used as a probe. Hybridization
and washing conditions were as recommended by CLONTECH. In these
conditions, y1LAT-1 and y1LAT-2 cRNAs were not detected (data not
shown).
In Situ Hybridization—Sense and antisense cRNA probes were la-
beled with digoxigenin-11-UTP (Roche Molecular Biochemicals) by
transcription of a LAT2 fragment (1–310 nt of the contig shown in Fig.
1) contained in the pT7T3D vector. The transcription reactions were set
up at room temperature by mixing 7.5 ml of double-distilled water
treated with diethyl pyrocarbonate, 1 ml of linearized template cDNA (1
mg), 4 ml of 53 transcription buffer (Promega), 2 ml of NTPmix (10 mM
ATP, CTP, GTP, 6.5 mM UTP, 3.5 mM digoxigenin-11-UTP, Roche
Molecular Biochemicals), 1 ml of RNAsin (30.6 units/ml, Amersham
Pharmacia Biotech), and 2 ml of RNA polymerase (T7 or T3, 15 units/ml,
Promega). Labeling reactions were performed at 37 °C for 2 h and
stopped by incubation with 2 ml of RNase-free DNase (10 units/ml,
Stratagene) for 15 min at 37 °C. cRNA fragments were precipitated
overnight with 1/10 vol of 4 M LiCl and 2.5 volumes of ethanol at
280 °C. The precipitated cRNA was recovered in 10 ml of double-
distilled water treated with diethyl pyrocarbonate.
Fresh human kidney was fixed in 4% paraformaldheyde, 0.1 M phos-
phate buffer and kept at 4 °C before use. Thereafter, the sections were
washed in 0.1 M phosphate buffer (2 h, room temperature) and dehy-
drated with 70, 90, and 100% alcohol, alcohol/xylene (v/v), and xylene (2
h for each). Pieces were embedded in paraffin. 5-mm sections were cut
on a Leica RM 2135 microtome and mounted on silenized slides (Perkin-
Elmer). Sections were deparaffined with xylene and hydrated with 100,
90, and 70% ethanol and double-distilled water treated with diethyl
pyrocarbonate, permeabilized with proteinase K (Roche Molecular Bio-
chemicals) (1 mg/ml) in Tris-EDTA buffer, pH 8 (3 min, 37 °C), 0.2 N
HCl (20 min, room temperature), and washed twice in 23 SSC solution
(30 min, room temperature). The hybridization step was carried out
with a solution containing 50% formamide, 10% dextran sulfate, 23
SSC solution, 13 Denhardt’s solution, 400 ng/ml denatured salmon
sperm DNA, and denatured (4 min, 70 °C) sense or antisense probes (5
ng/ml) for 16 h at 42 °C in a moist chamber. The sections were then
washed in 43 SSC solution containing 45% formamide (2 min, room
temperature), 0.13 SSC (1 h, 37 °C), digested with 20 mg/ml RNase A
(Roche Molecular Biochemicals) (30 min, room temperature), and
washed in 0.13 SSC solution (5 min, room temperature). Sections were
rinsed twice in Tris-buffered saline (TBS), pH 7.5 (10 min, room tem-
perature), blocked with 1% bovine serum albumin in TBS (30 min, room
temperature), and incubated overnight with an alkaline phosphatase-
conjugated anti-digoxigenin antibody (1:500) (Biocell, Cardiff, UK).
They were then washed in TBS, pH 7.5 (10 min, room temperature), and
TBS, pH 9.5, containing 50 mM MgCl2 (10 min, room temperature) and
developed with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl
phosphate (Roche Molecular Biochemicals). Slides were examined on an
Olympus microscope.
Chromosome Mapping—Chromosome mapping was done using the
Stanford Human Genome Center G3 radiation hybrid panel (medium
resolution). DNA samples of this panel, along with total genomic DNA
and pT7T3-249835 (used as a positive control), were PCR screened for
the presence of the genomic sequences flanked by the primers 12D
(59-GGCATCTCTCTTCCTAATG-39) and 7R (59-GCCAATGCTCTCCT-
CAGT-39), which are located in the 39-untranslated region of the cDNA.
PCR amplifications were carried out in a Perkin-Elmer 9600 thermo-
cycler as described elsewhere (3). Amplification conditions were as
follows: 35 cycles of denaturing (94 °C, 30 s), annealing (58 °C, 40 s),
and extension (74 °C, 30 s). PCR results were transformed into zeros
(for no amplification) and ones (for positive amplification) and submit-
ted to the radiation hybrid mapping e-mail server at the Stanford
Human Genome Center (SHGC). The resulting chromosomal location,
referred to a SHGC marker, was obtained automatically via e-mail from
this server.
Localization of LAT-2 Expression by Confocal Microscopy—Groups of
five oocytes were prepared for immunofluorescence 2 days after injec-
tion with 10 ng/oocyte human 4F2hc or N-myc-LAT-2 cRNA, alone or in
combination. Oocytes were placed in 500 mm3 cryomolds (Tissue-Tek,
Miles Inc., Elkhart, IN), sliced, fixed, and permeabilized as described
elsewhere (18). Slices were incubated with monoclonal antibody 9E10
anti-myc (ATCC, Manassas, VA), diluted 1/500 in 10% phosphate-buff-
ered saline, at room temperature for 1 h. Slices were washed three
times in phosphate-buffered saline, incubated with 7.5 mg/ml Texas
red-conjugated goat anti-mouse (Molecular Probes, Leiden, The Neth-
erlands) at room temperature for 1 h, washed three times in phosphate-
buffered saline, and mounted in Immunofluore (ICN, Madrid, Spain).
RESULTS
Our goal was to identify any new member of the amino acid
transporter-related family expressed in the kidney and poten-
tially involved in reabsorption of amino acids. For this purpose,
reverse transcription-PCR amplification of total RNA from
opossum kidney cells was performed with degenerated primers
as described for the identification of y1LAT-1 (3). Electro-
phoretic analysis of the PCR reaction showed one band of 286
bp, which was subcloned into pGEMT-easy vector and ampli-
fied in Escherichia coli. The deduced amino acid sequence of
one clone (b2c2) showed a significant degree of identity to the
amino acid transporter-related proteins: 46, 45, 43, 41, and
43% with human y1LAT-1 and y1LAT-2 and Xenopus, rat, and
human LAT-1, respectively. This homology is compatible with
the assumption that b2c2 is part of a cDNA corresponding to a
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new member of this family. By using the same computer ap-
proach (BLAST and EST Cluster Assembly Machine) as we
recently used for the identification of y1LAT-1 (3), a human
EST (W39098, IMAGE clone 322502) that shows homology
with the b2c2 fragment (92% identity in the amino acid se-
quence) was identified. Subsequently, EST W39098 was used
to identify two other ESTs from the same cluster (N23973 and
H84042, from IMAGE clones 267204 and 249835, respectively).
Sequences of these overlapping EST clones revealed a 39-polya-
denylated cDNA contig (LAT-2) of 3733 bp (Fig. 1). The first
ATG codon lies within a good consensus initiation sequence
(59-GAAGG) (21). The ORF continues to the first stop codon
(TGA) at base 1827 and codes for a protein of 535 amino acid
residues with a predicted molecular mass of 58,577 Da. The
nucleotide sequences of EST clones 322502, 267204, and
249835 and LAT-2 cDNA have been deposited in the Gen-
Banky/EBI data base (accession numbers AF135828,
AF135829, AF135830, and AF135831, respectively).
A multiple sequence alignment of the predicted amino acid
sequence of human LAT-2, LAT-1, y1LAT-1, and y1LAT-2 is
shown in Fig. 2. Human LAT-2 shows an amino acid sequence
identity of 50, 44, and 45% to human LAT-1, y1LAT-1 and
y1LAT-2, respectively. Hydrophobicity studies show 12 trans-
membrane domains with both C- and N-terminal segments
intracytoplasmatic, which is the same protein structure sug-
gested for the other members of this family (1–3, 19). Only the
consensus for the position of the transmembrane segment III
can vary for the proteins presented in Fig. 2. There is only one
putative N-glycosylation site (Fig. 2, boxed) between the puta-
tive transmembrane segments VIII and IX. In our predicted
model this segment is cytoplasmic and cannot be glycosylated.
This finding is in full agreement with previous expression
studies with rat and human LAT-1 (1–2). 4F2hc is associated
with its subunits in a disulfide bond-dependent manner (2–4,
22) through cysteine residue 109 of human 4F2hc (18) and
cysteine residue 164 of Xenopus LAT-1 (23). This cysteine res-
idue is conserved in all human 4F2 light chains including
LAT-2 (cysteine residue 154) (Fig. 2).
The human LAT-2 gene was chromosome-mapped by using a
radiation hybrid panel (see “Experimental Procedures”) with
primers corresponding to the 39-untranslated region of the
LAT-2 cDNA. From this screening we obtained 16 positive and
66 negative results. Chromosome mapping results, obtained
from the SGHC server, linked Lat-2, with a logarithem odds
score of 12.6, to a distance of 13 cR (286 kb) from the marker
SHGC-13507 (D14S1349). The nearest centromeric marker to
this one, marker SHGC-6999 (X52889), is located at chromo-
some 14q11.2–13.
cRNA from LAT-2 was injected into oocytes alone or in com-
bination with an equimolar quantity of human 4F2hc cRNA
and tested for amino acid transport (Fig. 3). 4F2hc alone in-
duced, as previously reported (16, 18, 24–27), y1L amino acid
transport activity (i.e. sodium-independent L-arginine trans-
port and sodium-dependent L-leucine transport). LAT-2 alone
induced weakly sodium-independent L-leucine transport. Inter-
estingly, when 4F2hc and LAT-2 were co-injected, the induc-
tion of L-arginine transport was lower than that induced by
4F2hc alone, whereas the induction of sodium-independent
L-leucine transport increased dramatically (Fig. 3). From four
independent experiments the average co-expression of L-
leucine transport relative to the induction of 4F2hc alone was
30-fold (ranging from 6- to 100-fold). The co-expression of
leucine transport by 4F2hc and LAT-2 is sodium-independent,
suggesting induction of a system L-type amino acid transport
activity (Fig. 3). Kinetic analysis revealed an apparent Km of
221 6 54 mM for the transport of L-leucine induced by 4F2hc/
FIG. 1. Nucleotide and deduced amino acid sequence of LAT-2
cDNA. The size of the cDNA contig is 3733 bp, containing a 59-untrans-
lated region of 221 bp followed by an ORF of 535 amino acids and a
39-untranslated region of 1904 bp that contains a 23-bp long poly(A)
tail. The stop codon (TGA) is indicated by a star. The possible poly-
adenylation signal is underlined. The sequences of the overlapping
segments were identical in all three clones except for nt 1422. At this
position, clone 267204 has a G, as in the ESTs N32639 and N31874, and
the corresponding amino acid residue is Val401. In contrast, clone
249835 has an A, and the corresponding amino acid is Ile401. This is
probably a polymorphism. In agreement with the majority of available
EST sequences, the contig LAT-2 shown in this figure and the cRNA
injected in this study has G at position 1422 (i.e. Val401).
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LAT-2 (data not shown).
To further characterize the uptake activity co-expressed by
LAT-2 and 4F2hc, we measured the inhibition of sodium-inde-
pendent leucine uptake by different amino acids at a 100-fold
excess concentration (5 mM). Fig. 4 shows the inhibition pattern
for the transport activity induced by LAT-2 and 4F2hc com-
pared with that induced by X. laevis LAT-1 and 4F2hc. These
results showed clearly that the transport activity induced by
4F2hc/LAT-2 and 4F2hc/LAT-1 is restricted to zwitterionic
amino acids. The pattern of inhibition in the case of X. laevis
LAT-1, restricted to large zwitterionic amino acids and analogs
(i.e. BCH), is in full agreement with the pattern described for
rat LAT-1 (1). In contrast, 4F2hc/LAT-2-induced transport ac-
tivity was also practically abolished by small zwitterionic
amino acids (i.e. glycine, alanine, serine, threonine, and cys-
teine), and it is clearly inhibited by glutamine and asparagine.
To demonstrate transport of small zwitterionic amino acids via
FIG. 3. Co-expressed amino acid transport activity by 4F2hc
and LAT-2. Oocytes were injected with LAT-2 cRNA alone or in com-
bination with human 4F2hc cRNA. Three days after the injection, the
uptake of 50 mM L-[3H]arginine (Arg) and 50 mM L-[3H]leucine (Leu) in
the presence (1, slashed bars) or absence (2, open or closed bars) of 100
mM NaCl was determined for 5 min. Transport of L-[3H]leucine in the
absence of sodium is highlighted in the closed bars. Amino acid uptake
rates (pmol/5 min per oocyte) were calculated by subtracting the uptake
of the noninjected group from that of the cRNA-injected groups. The
amino acid uptake activity of uninjected oocytes was as follows:
L-[3H]arginine uptake, 3.0 6 0.2 (choline medium) and 4.0 6 0.7 (sodi-
um medium); L-[3H]leucine uptake, 1.8 6 0.2 (choline medium) and
3.3 6 0.4 (sodium medium). Data (mean 6 S.E.) correspond to a repre-
sentative experiment with 7–8 oocytes per group.
FIG. 4. Inhibition pattern of the amino acid transport activity
co-expressed by 4F2hc and LAT-2. Two or 3 days after injection of
4F2hc cRNA together with LAT-2 or LAT-1 cRNA, the uptake of 50 mM
L-[3H]leucine in the absence of sodium was measured for 5 min in the
absence (Control) or in the presence of the indicated amino acids or
analogs at 5 mM. The expressed transport (i.e. subtracting transport of
noninjected oocytes) in control groups was 15.3 6 1.5 and 26.6 6 4.0
pmol/5 min per oocyte for 4F2hc/LAT-2- and 4F2hc/LAT-1-injected oo-
cytes, respectively. Data (mean 6 S.E.) represent percentages of the
amino acid residual transport in the presence of inhibitors. Transport of
L-[3H]leucine in noninjected oocytes was 1.6 6 0.2 pmol/5 min per
oocyte. Data correspond to two to four independent experiments, in
which 7–8 oocytes were used per group in each experiment.
FIG. 2. Amino acid sequence com-
parison of the four human members
of the family of amino acid transport-
ers that are subunits of 4F2hc. Multi-
alignment was done using the program
CLUSTALW Sequence Alignment from
the Baylor College of Medicine. The thin
horizontal lines indicate the 12 putative
transmembrane domains determined by
computer analysis (see “Experimental
Procedures”). The amino acid residues
identical to LAT-2 sequence are indicated
in gray boxes. The solid frame box indi-
cates a potential N-glycosylation site, but
according to our membrane topology pre-
diction, this site is intracellular and can-
not be glycosylated. The conserved cys-
teine residue is indicated with a star.
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this variant of system L, the uptake of 50 mM L-[3H]alanine was
determined in oocytes expressing 4F2hc/LAT-2 or 4F2hc/
LAT-1. Interestingly, co-expression of 4F2hc/LAT-2 in oocytes,
but not of 4F2hc/LAT-1, resulted in the induction of L-alanine
transport above background (i.e. noninjected or 4F2hc-injected
oocytes) (Fig. 5a). Kinetic analysis of this transport revealed an
apparent Km of 978 6 142 mM (Fig. 5b). Similarly to alanine,
4F2hc/LAT-2 induced sodium-independent L-glutamine trans-
port. Two days after injection, the induced uptake of 200 mM
L-[3H]glutamine was 0.3 6 0.4 and 34.6 6 4.0 pmol/5 min per
oocyte for 4F2hc- and 4F2hc/LAT-2-injected oocytes, respec-
tively. All of the above suggests that 4F2hc/LAT-2 represents a
broad specificity variant of system L transporter for small and
large zwitterionic amino acids.
In agreement with previous reports for the transport activity
induced by 4F2hc in oocytes (18, 20) by LAT-1/4F2hc (1–2) and
y1LAT-1/4F2hc (4), LAT-2/4F2hc showed a high level of trans-
stimulation. Fig. 6 shows that the efflux of L-[3H]isoleucine in
oocytes expressing LAT-2/4F2hc is dependent on the presence
of a substrate in the medium (e.g. leucine), but it is not trans-
stimulated by amino acids that are not substrates (e.g. proline)
of LAT-2/4F2hc amino acid transporter. The level of efflux in
trans0 conditions (no amino acid substrates in the medium) in
oocytes expressing LAT-2/4F2hc is identical to that of non-
injected oocytes or oocytes expressing 4F2hc alone (Fig. 6).
This result suggests a high level of exchanger coupling via
LAT-2/4F2hc.
Recently, it has been shown that y1LAT-1, LAT-1, and
SPRM1 form a disulfide bond heterodimeric complex with
4F2hc (2–4, 22, 23). Moreover, Verrey and co-workers (2) have
shown that 4F2hc brings SPRM1 to the oocyte plasma mem-
brane. Fig. 7 shows that 4F2hc also brings LAT-2 to the oocyte
plasma membrane. To follow the expression of LAT-2, a tagged
LAT-2 cRNA (N-myc-LAT-2) was expressed in oocytes. N-myc-
LAT-2 co-expresses with 4F2hc L-transport activity, but N-myc-
LAT-2 alone does not induce amino acid transport activity (see
legend to Fig. 7). Confocal immunofluorescence detected N-
myc-LAT-2 at the oocyte plasma membrane when co-expressed
with 4F2hc, but its expression was intracellular when ex-
pressed alone in oocytes (Fig. 7).
The tissue expression of the mRNA corresponding to LAT-2
was examined by Northern blot analysis at high stringency
conditions (Fig. 8). mRNA species of ;5 and ;3.7 kb hybridize
with the LAT-2 cDNA; the size of the shorter transcript corre-
sponds to that of the LAT-2 cDNA identified here. Both tran-
scripts are expressed most conspicuously in the kidney. Pla-
centa .. brain, liver . skeletal muscle, and heart also express
these transcripts. The last two also showed a very faint band of
;7 kb. Long exposures also revealed the 5- and 3.7-kb tran-
scripts in the small intestine and the lung. In situ hybridization
studies specifically localized the renal expression of LAT-2
mRNA to the epithelial cells of proximal tubules, most probably
in the convoluted part (Fig. 9). No other components of the
nephron, including distal tubules and glomeruli, were reactive
with LAT-2 cRNA probe. A similar pattern of expression has
been shown on inmunolocalization of 4F2hc protein on kidney
cortex (Ref. 28, and data not shown).
FIG. 5. 4F2hc/LAT-2 co-expresses alanine transport in oocytes.
a, oocytes were injected with 4F2hc cRNA alone or in combination with
LAT-1 or LAT-2 cRNA. Three days after the injection, the uptake of 50
mM L-[3H]alanine in the absence of sodium was determined for 5 min.
Transport of noninjected oocytes was 6.5 6 1.1 pmol/5 min per oocyte.
Data (mean 6 S.E.) correspond to a representative experiment with 7–8
oocytes per group. Another two independent experiments showed sim-
ilar results. b, kinetic analysis of L-alanine transport co-expressed by
4F2hc/LAT-2. Oocytes were injected with 4F2hc and LAT-2 cRNA. Two
days after the injection, the uptake of L-[3H]alanine in the absence of
sodium was determined for 5 min at different substrate concentrations
(10, 25, 50, 100, 150, 250, 500, 1000, 2000, and 5000 mM). The transport
activity level in noninjected oocytes was subtracted from that of cRNA-
injected oocytes. Data (mean 6 S.E.) correspond to a representative
experiment with 5–6 oocytes per group. Kinetic parameters were: Vmax
5 64 6 7 pmol/5 min per oocyte, Km 5 978 6 143 mM, and r (correlation
coefficient) 5 0.92 (p # 0.001).
FIG. 6. Trans-stimulation of efflux via 4F2hc/LAT-2 system L.
Oocytes were injected with 4F2hc cRNA alone or in combination with
LAT-2 cRNA. Three days after the injection, oocytes were loaded with
50 mM L-[3H]isoleucine for 60 min reaching the following uptake level of
radioactivity: 21900 6 1900, 3700 6 400, and 2200 6 400 cpm per
oocyte in 4F2hc/LAT-2-injected, 4F2hc-injected, and noninjected oo-
cytes, respectively. The efflux of radioactivity was then measured in the
indicated periods of time in media containing 1 mM L-leucine (Leu, f) or
proline (Pro, M) or no amino acids (none, E). Data (mean 6 S.E.)
correspond to a representative experiment with three groups of 5 oo-
cytes per data point. The efflux rates in 4F2hc-injected and noninjected
oocytes in the presence of 1 mM L-leucine in the medium were 1630 6
200 and 1350 6 100 3 103 cpm/5 oocytes per min, respectively. These
efflux rates are indistinguishable from those of 4F2hc/LAT-2-injected
oocytes in medium containing 1 mM proline or no amino acids.
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DISCUSSION
In this study we have identified a new member (LAT-2) of the
family of amino acid transporters, which are subunits of 4F2hc
and in humans are composed also of LAT-1, y1LAT-1, and
y1LAT-2. We report here on the human LAT-2 cDNA sequence,
chromosomal location, and pattern of expression of its mRNA.
Moreover, we show that 4F2hc brings LAT-2 to the oocyte
plasma membrane, which induces a system L amino acid trans-
port activity with broad specificity. Therefore, LAT-2 is a pu-
tative new light subunit of the surface antigen 4F2.
Before the identification of the 4F2hc subunits, functional
expression experiments in oocytes revealed that 4F2hc induced
both system y1L (16, 24–27) and system L (29) transport
activities. In agreement with this finding, the 4F2hc subunits
y1LAT-1, y1LAT-2, LAT-1, and LAT-2 are isoforms of systems
y1L and L, respectively. Before our cloning of system y1L,
there were no reports of variants of system y1L in the litera-
ture (30). y1LAT-1 is defective in lysinuric protein intolerance
(5, 6), and y1LAT-2 might be responsible for system y1L in the
cell types in which this transport activity is not defective in
lysinuric protein intolerance (e.g. erythrocytes (31)). In con-
trast, system L variants L1 (substrate affinity in the micromo-
lar range) and L2 (substrate affinity in the millimolar range)
have been described previously (10). These subtypes are ex-
pressed in hepatoma cell lines and hepatocytes, respectively
(11). An L3 subtype was described in fibroblasts with an affin-
ity between that of the L1 and L2 subtypes (12). LAT-1 fits the
transport characteristics and the tissue distribution of subtype
L1 (Ref. 1 and present study). LAT-2 shows characteristic
features of system L (i.e. sodium-independent transport of zwit-
terionic amino acids inhibitable by the analog BCH), but it also
shows features that are dissimilar to both system L subtypes.
Thus, LAT-2 is expressed in the liver and has a substrate
affinity in the micromolar range for L-leucine (Km '220 mM).
This is a lower affinity than has been described for rat (18 mM)
and Xenopus (32 mM) LAT-1 (1, 2). Moreover, in contrast to the
hepatic system L, LAT-2 also transports small zwitterionic
amino acids (e.g. L-alanine with an apparent Km ' 1 mM). A
transport system with similar characteristics (sodium-inde-
pendent, trans-stimulated transport for large and small zwit-
terionic amino acids and a similar apparent Km for L-alanine) to
that of LAT-2 has been described in the basolateral membrane
of the intestinal enterocyte (32, 33) and the placental syncy-
tiotrophoblast (34).
What is the physiological role of a system L transporter with
broad specificity for zwitterionic amino acids, including the
small ones? Christensen (10) hypothesized that system L
serves the exchange (efflux and influx) of zwitterionic amino
acids through the plasma membrane to fulfill the inter-organ
fluxes of these amino acids (10). The transport activity induced
by 4F2hc/LAT-2 is highly trans-stimulated in oocytes. Indeed,
LAT-2 behaves as an exchanger, because the efflux via this
transporter in oocytes is totally dependent on the presence of a
substrate in the medium. The kidney showed the highest
LAT-2 mRNA expression (present study), whereas LAT-1, the
other system L isoform transporter, is not expressed in the
kidney (1). The involvement of rBAT and y1LAT-1 in Type I
cystinuria and lysinuric protein intolerance, respectively (5, 6,
9), demonstrates the role of these transporters in the apical
reabsorption of cystine and dibasic amino acids (rBAT) and in
the basolateral efflux of dibasic amino acids (4F2hc/y1LAT-1).
LAT-2 mRNA is restricted to the epithelial cells of the proximal
tubule of the human kidney (present study). In these cells
4F2hc has a basolateral location (28). This result suggests that
FIG. 7. Localization of N-myc-LAT-2 in oocytes. Oocytes were
injected with myc-tagged LAT-2 or 4F2hc cRNA alone or in combina-
tion. Three days later oocytes were processed for immunocytochemistry
with mAb 9E10 anti-myc as primary antibody and Texas red-conju-
gated goat anti-mouse as secondary antibody (see “Experimental Pro-
cedures”). Micrographs show that 4F2hc brings N-myc-LAT-2 to the
oocyte plasma membrane. The myc-immunodetected signal (white) is
visible inside the oocyte when expressed alone, but it is at the plasma
membrane when co-expressed with 4F2hc. The signal is almost absent
in 4F2hc-injected oocytes. Two days after injection the induced uptake
of 100 mM L-[3H]leucine in pmol/5 min per oocyte was 0.2 6 1.0 for
N-myc-LAT-2, 0.9 6 0.3 for 4F2hc, 37.8 6 3.9 for 4F2hc/LAT-2, and
19.2 6 3.3 for 4F2hc/N-myc-LAT-2.
FIG. 8. Northern blot analysis for LAT-2 mRNA in human tis-
sues. A poly(A) RNA membrane (2 mg per lane) containing 12 different
human adult tissues was purchased from CLONTECH. Blots were
probed with 32P-labeled human IMAGE clone 267204 and washed at
high stringency conditions (see “Experimental Procedures”). Human
LAT-2 cDNA hybridizes to transcripts of ;5 and ;3.7 kb and is ex-
pressed in kidney ... placenta .. brain, liver . spleen, skeletal
muscle, heart, small intestine, and lung. A transcript of ;7 kb is also
visible in skeletal muscle and heart. The leukocyte sample is from
peripheral blood.
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4F2hc/LAT-2 might mediate the efflux of zwitterionic amino
acids, including those with a short side chain, through the
basolateral plasma membrane. Moreover, the fact that cys-
teine, the main intracellular form of cystine (35, 36), strongly
inhibits 4F2hc/LAT-2 transport activity suggests the role of
this transporter in the renal reabsorption of cystine. The ex-
pression of LAT-2 mRNA in the small intestine suggests a
similar role in the intestinal absorption of zwitterionic amino
acids. The expression of LAT-2 mRNA in the placenta also
implicates it in the transfer of zwitterionic amino acids from
the placenta to the fetus. This hypothesis needs confirmation
by the localization of LAT-2 at the basolateral plasma mem-
brane in the epithelial cells of the proximal tubule and in the
placental trophoblast. The expression of LAT-2 mRNA in the
brain, liver, spleen, and skeletal muscle suggests a role in the
release of glutamine and short zwitterionic amino acids from
these tissues as follows: (i) glial cells release glutamine to
neurons as a substrate for glutamate and g-aminobutyric acid
synthesis (37); (ii) hepatocytes in the perivenous zone release
glutamine as an ammonium detoxification pathway (38); (iii)
the skeletal muscle releases most of the aminic nitrogen as
glutamine and alanine (39); and (iv) spleen and small intestinal
enterocytes metabolize glutamine and produce alanine and
other small zwitterionic amino acids (e.g. serine and glycine)
(40). Identification of the cells expressing LAT-2 in these tis-
sues will help us to understand the role of this system L amino
acid transporter with broad specificity.
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8. Palacı́n, M., Estévez, R., Bertran, J., and Zorzano, A. (1998) Physiol. Rev. 78,
969–1054
9. Calonge, M. J., Gasparini, P., Chillarón, J., Chillón, M., Gallucci, M., Rousaud,
F., Zelante, L., Testar, X., Dallapiccola, B., Di Silverio, F., Barceló, P.,
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FIG. 9. In situ hybridization of LAT-2 mRNA in human adult
kidney. Serial paraffin-embedded sections of human kidney cortex
were stained with hematoxylin-eosin (a) or incubated with antisense (b)
or sense (c) LAT-2 cRNA probes as described under “Experimental
Procedures.” Results are representative of two independent experi-
ments. LAT-2 mRNA-specific detection is restricted to proximal tubule
(PT) epithelial cells (some proximal tubules are indicated by arrows).
The proximity of these tubules to the glomerulus (G) suggests a local-
ization of LAT-2 mRNA signal in the proximal convoluted part. No
other specific signal was detected in the renal cortex. Bar 5100 mm.
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